3D方案治疗初始治疗的基因1b型慢性丙型肝炎患者疗效研究*

doi:10.3969/j.issn.1672-5069.2025.06.007

Abstract

Abstract: Objective The aim of this study was to investigate the antiviral efficacy of 3D regimen in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C (CHC). Methods A total of 102 patients with genotype 1b-infeced CHC were enrolled in our hospital between January 2020 and December 2024, and all the naïve patients received paritaprevir, ritonavir, ombitasvir and dasabuvir combination antiviral therapy for 12 weeks. Blood, biochemical and virological parameters were routinely detected. Controlled attenuation parameter(CAP) and liver stiffness measurement (LSM) were detected by Fibrotouch. Results Serum HCV RNA load at baseline in the 102 patients with CHC was(6.2±0.7)lg copies/ml, and by end of 2 week, 4 week, 8 week, 12 week of antiviral treatment, and 12 week and 24 week of follow-up, it decreased to (5.1±1.4)lg copies/ml, (3.7±0.9)lg copies/ml, (2.4±0.7)lg copies/ml, (1.1±0.3)lg copies/ml, and (0.7±0.3)lg copies/ml and (0.7±0.3)lg copies/ml, respectively; the end-treatment virological response (VR) was 96.1%, and the sustained virological response (SVR) 12 and SVR 24 w were 93.1% and 93.1%, respectively; serum ALT and AST levels at presentation were (81.3±7.8)U/L and (58.7±6.4)U/L, and after four week antiviral treatment, they turned back to normal gradually; baseline peripheral white blood cell count, platelet count, LSM and CAP in the series were (6.8±1.3)×10⁹/L, (205.4±47.1)×10⁹/L, (8.9±0.6)kPa and (255.4±8.9)dB/m, by end of antiviral treatment, they were (6.7±1.1)×10⁹/L, (213.7±52.9)×10⁹/L, (8.5±0.5)kPa and (253.7±10.1)dB/m, and by end of 24 week follow-up, they changed to (6.9±1.1)×10⁹/L, (215.8±54.3)×10⁹/L, (8.1±0.4)kPa and (256.9±8.4)dB/m, respectively, apart from LSM decreased greatly (P<0.05) at end of 24 week follow-up, all without significant differences (P>0.05). Conclusion Short-term antiviral efficacy of 3D regimen is satisfactory and safe in patients with naïve genotype 1b-infected CHC, which needs long-term clinical observation.

Key words: Hepatitis C, Genotype 1b, Paritaprevir/ritonavir/ombitasvir/ dasabuvir, Virologic response, Adverse reaction, Therapy

Wang Chaojie, Xie Qun, Jiang Hai, et al. Antiviral efficacy of 3D regimen in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C[J]. Journal of Practical Hepatology, 2025, 28(6): 826-829.

References

[1] Jing JS, Wang ZQ, Jiang YK, et al. Association of cytokine gene polymorphisms with chronic hepatitis C virus genotype 1b infection in Chinese Han population: An observational study. Medicine (Baltimore), 2020, 99(38):e22362.
[2] Fedorchenko SV, Martynovych T, Klimenko Z, et al. Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin. J Viral Hepat, 2020, 27(5):548-551.
[3] 张珂瓈,童静,李昌平.接受达拉他韦和阿舒瑞韦治疗的初始治疗基因1b型慢性丙型肝炎患者疗效评价.实用肝脏病杂志,2024,27(6):840-843.
[4] 李兴泉,杨春,李诗源,等.奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎患者疗效研究.实用肝脏病杂志,2024,27(2):177-180.
[5] Örmeci N, Gülşen MT, Sezgin O, et al. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol, 2020, 31(2):148-155.
[6] Fedorchenko SV, Martynovych T, Klimenko Z, et al. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors. J Med Virol, 2021, 93(8):4975-4981.
[7] 韩宏艳,潘娟,蒋文平,等.3D方案治疗基因1b型低病毒载量慢性丙型肝炎患者应答疗效研究.实用肝脏病杂志,2021,24(5):689-692.
[8] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2019年更新版.实用肝脏病杂志,2020,23(1):S33-52.
[9] Cheng XD, Xu HF, Wei F, et al. The genotype analysis of the hepatitis C virus in Heilongjiang Province, China. Medicine (Baltimore), 2021, 100(18):e25203.
[10] 刘雅光,胡连智,董一侠,等.抗病毒治疗的基因1b型慢性丙型肝炎患者疗效及其血清γ-干扰素和白细胞介素-10水平变化.实用肝脏病杂志,2024,27(5):689-692.
[11] Magri MC, Manchiero C, Prata TVG, et al. The influence of gene-chronic hepatitis C virus infection on hepatic fibrosis and steatosis. Diagn Microbiol Infect Dis, 2020, 97(2):115025.
[12] Mattingly TJ 2nd, Slejko JF, Onukwugha E, et al. Value in hepatitis c virus treatment: a patient-centered cost-effectiveness analysis. Pharmacoeconomics, 2020, 38(2):233-242.
[13] Fuchs M, Monto A, Bräu N, et al. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders. J Med Virol, 2020, 92(12):3459-3464.
[14] Deutsch L, Houri I, Ben-Ari Z, et al. Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial. BMC Infect Dis, 2020, 20(1):264.
[15] Jitta SR, Salwa, Bhaskaran NA, et al. Recent advances in nanoformulation development ofritonavir, a key protease inhibitor used in the treatment of HIV-AIDS. Expert Opin Drug Deliv, 2022, 19(9):1133-1148.
[16] Mandelbrot L, Tubiana R, Frange P, et al. Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study. J Antimicrob Chemother, 2023, 78(7):1711-1722.
[17] Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs. Clin Infect Dis, 2023, 76(1):165-171.
[18] Değertekin B, Demir M, Akarca US, et al. Real-world efficacy and safety of ledipasvir + sofosbuvir and ombitasvir/paritaprevir/ritonavir ± dasabuvir combination therapies for chronic hepatitis C: A Turkish experience. Turk J Gastroenterol, 2020, 31(12):883-893.
[19] Moreno G, Carbonell R, Díaz E, et al. Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection: A multicentre cohort study. J Med Virol, 2023, 95(8):e29010.
[20] Neuberger E, Wallick C, Chawla D, et al. Baloxavir vs oseltamivir: reduced utilization and costs in influenza. Am J Manag Care, 2022, 28(3):e88-e95.
[21] Hung HY, Chen CY, Liao YH. Aretrospective cohort study: safety and effectiveness of elbasvir/grazoprevir ± ribavirin compared with ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin in patients with chronic hepatitis c genotype 1 infection. Front Pharmacol, 2021, 12:640317.
[22] Chen S, Gao Y, Lou X, et al. Overcoming bioavailability challenges of dasabuvir and enabling a triple-combination direct-acting antiviralHCV regimen through a salt of very weak acid for oral delivery. Mol Pharm, 2022, 19(7):2367-2379.

Antiviral efficacy of 3D regimen in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yao Yu, Ning Bo. Pathogenesis,spontaneous recanalization and anticoagulation therapy in patients with liver cirrhosis and portal vein thrombosis [J]. Journal of Practical Hepatology, 2025, 28(6): 801-804.
[2]	Li Sisi, Jiang Yanzhen, Fu Zhaoyuan. Chinese traditional and western medicine in the treatment of liver fibrosis:current state of the art, controversies, and perspectives [J]. Journal of Practical Hepatology, 2025, 28(6): 805-808.
[3]	Hua Qi, Liu Qiong, Chen Qi. Rescue antiviral therapy of tenofovir alafenamide in entecavir-treated chronic hepatitis B patients with low level viremia [J]. Journal of Practical Hepatology, 2025, 28(6): 818-821.
[4]	Jiang Chanjuan, Shao Jingyuan, Xu Lin. Efficacy and safety of albavir/gravir in the treatment of patients with chronic hepatitis C with underlying chronic renal disease [J]. Journal of Practical Hepatology, 2025, 28(6): 822-825.
[5]	Li Hui, Tao Ya, Xu Xunmei, et al. Efficacy of liraglutide in the treatment of patients with NAFLD and T2DM and its impact on peripheral blood mononuclear cell NLRP3, Caspase-1 and ASC levels [J]. Journal of Practical Hepatology, 2025, 28(6): 830-833.
[6]	Zheng Huihui, Wang Yurong, Xu Ting. Combination of Xuezhikang and atorvastatin in treatment of patients with non-alcoholic fatty liver disease and hyperlipidemia [J]. Journal of Practical Hepatology, 2025, 28(6): 834-837.
[7]	Wang Meiling, Li Jie, Liu Juan, et al. Semaglutide in combination with fenofibrate in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(6): 838-841.
[8]	Gao Hai’na, Liang Pan, Gao Linhui, et al. Combination of exenatide and metformin in treatment of patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: A pilot study [J]. Journal of Practical Hepatology, 2025, 28(6): 842-845.
[9]	Chen Xiaoling, Zhang Panpan, Fu Yufang, et al. Clinical efficacy of semaglutidein combination with Huatan Quyu Tongluo decoction in the treatment of patients with NAFLD and T2DM: A pilot study [J]. Journal of Practical Hepatology, 2025, 28(6): 846-849.
[10]	Tian Weiwei, Sun Jiaqi, Chen Ken, et al. Efficacy of standard immunosuppressive therapy with combination of diammonium glycyrrhizinate in the treatment of patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2025, 28(6): 854-857.
[11]	Huang Xiaoli, Shen Jie. Entecavir antiviral treatment with daily outcutaneous irradiation of infrared ray in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(6): 878-881.
[12]	Yang Lan, Xu Shijie, Bao Huaxin. Serum FGFR1, VEGFA and IRX5 level changes in patients with hepatocellular carcinoma after TACE treatment [J]. Journal of Practical Hepatology, 2025, 28(6): 890-893.
[13]	Li Jianlin, Li Ya, Zheng Qiuran, et al. ¹²⁵I radioactive seed implantation in combination with TACE in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2025, 28(6): 894-897.
[14]	Tian Tanping, Yang Dinghua, Song Xin, et al. Local TACE with combination of immune and targeted therapy in the treatment of patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2025, 28(6): 898-901.
[15]	Guo Jianwei, Jia Jianfeng, Yang Chun, et al. Multimodal ultrasound in evaluating microvascular invasion in patients with primary liver cancer receiving transarterial chemoembolization [J]. Journal of Practical Hepatology, 2025, 28(6): 902-905.